Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Capsule type inhalation dust cloud agent

A technology for inhaling powder aerosols and capsules, which is applied to the field of capsule-type inhalation powder aerosols, can solve the problems of less drug deposition, influence on curative effect, and high production cost, and achieve the effect of increasing deposition amount

Active Publication Date: 2009-04-08
HONGYI SCI & TECH CO LTD NANCHANG
View PDF0 Cites 4 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

The development of dry powder inhalation devices in China is quite lagging behind. At present, the commercially available ones are mainly the Tianping brand dry powder inhalation devices of Shanghai Tianping Pharmaceutical Factory. It is very similar to the Spinhaler that came out first abroad. less, affect the curative effect
Dura Corporation of the United States is developing a dry powder inhalation device with a micro-motor to overcome the defects of existing devices, but the production cost is high

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Capsule type inhalation dust cloud agent
  • Capsule type inhalation dust cloud agent
  • Capsule type inhalation dust cloud agent

Examples

Experimental program
Comparison scheme
Effect test

example 1

[0074] The micronized active ingredient is tiotropium bromide with a particle size of 1.07 μm to 3.06 μm; the glycine carrier has a maximum particle size of 80 μm and an average particle size of 50 μm to 75 μm.

[0075] The fluidity angle of repose of the dry powder composition made of micronized tiotropium bromide and glycine carrier is 56°.

[0076] The hygroscopicity of the dry powder composition made of micronized tiotropium bromide and glycine carrier was 7.5% relative weight gain.

[0077] use The emptying rate of the dry powder inhalation device was 98.6%, and the drug deposition in the effective part was 20.6%.

[0078] The dry powder composition made of micronized tiotropium bromide and glycine carrier has no obvious irritation and allergic reaction.

[0079] The results of influencing factor test, accelerated test and long-term test show that the quality is stable.

example 2

[0081] The micronized active ingredient is tobramycin with a particle size of 2.01 μm to 3.54 μm; the glycine carrier has a maximum particle size of 135 μm and an average particle size of 70 μm to 105 μm.

[0082] The fluidity angle of repose of the dry powder composition made of micronized tobramycin and glycine carrier is 53°.

[0083] The hygroscopicity of the dry powder composition made of micronized tobramycin and glycine carrier was 5.5% relative weight gain.

[0084] use The emptying rate of the dry powder inhalation device was 96.8%, and the drug deposition in the effective part was 17.6%.

[0085] The dry powder composition made of micronized tobramycin and glycine carrier has no obvious irritation and allergic reaction.

[0086] The results of influencing factor test, accelerated test and long-term test show that the quality is stable.

example 3

[0088] The micronized active ingredient is ribavirin with a particle size of 1.21 μm to 2.14 μm; the glycine carrier has a maximum particle size of 115 μm and an average particle size of 50 μm to 95 μm.

[0089] The fluidity angle of repose of the dry powder composition made of micronized ribavirin and glycine carrier is 56°.

[0090] The hygroscopicity of the dry powder composition made of micronized ribavirin and glycine carrier was 5.4% relative weight gain.

[0091] use The emptying rate of the dry powder inhalation device was 97.9%, and the drug deposition in the effective part was 21.3%.

[0092] The dry powder composition made of micronized ribavirin and glycine carrier has no obvious irritation and allergic reaction.

[0093] The results of influencing factor test, accelerated test and long-term test show that the quality is stable.

[0094] 4. Example 4

[0095] The micronized active ingredient of the present invention is albuterol sulfate with a particle size of...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

PropertyMeasurementUnit
Granularityaaaaaaaaaa
Maximum granularityaaaaaaaaaa
Average particle sizeaaaaaaaaaa
Login to View More

Abstract

The invention relates to a capsulated powder inhalation, which is characterized in that the capsulated powder inhalation is a dry powder composition made of a micronization active component and a glycine carrier and in the form of capsule, wherein the active component is inhaled by a patient from the oral cavity to a lung drug delivery system by using a specially made Helioeast<R> dry-powder inhaling device; the particle size of the active component is between 0.1 and 5 mu m, and the largest particle size is not more than 10 mu m; and the particle size of the glycine carrier is between 10 and 100 mu m, and the largest particle size is not more than 150 mu m. The capsulated powder inhalation has the advantages of high emptying rate of the dry powder and high deposition of the active component in the lung, good security and stability, and improvement on medication compliance of patients.

Description

technical field [0001] The invention relates to a capsule-type inhalation powder, which is characterized in that it is a dry powder composition made of a micronized active ingredient and a glycine carrier in the form of a capsule, using a special Dry powder inhalation device, a drug delivery system that aerosolizes active ingredients from the patient's mouth to the lungs. Background technique [0002] At present, drug therapy mainly adopts oral administration and injection administration. However, oral administration has the problems of gastrointestinal degradation, hepatic first-pass effect and low bioavailability; and injection administration, especially for chronic diseases and major epidemic diseases, has pain, inconvenience and safety. sexual hazard. Therefore, the development of a safe, effective, convenient, and highly bioavailable non-injection drug delivery system has become an urgent problem to be solved in the research of global pharmaceutical drug release tech...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
IPC IPC(8): A61K9/14A61K9/72A61K47/18
Inventor 刘孝乐钱进陶琳刘春阳
Owner HONGYI SCI & TECH CO LTD NANCHANG
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com